Limited Clinical Significance of Dimeric Form of Pyruvate Kinase as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Cancer
作者： Adam Rzechonek , Aleksandra Kaminska , Piotr Mamczur , Arkadiusz Drapiewski , Władysław Budzynski
DOI: 10.1007/5584_2016_92
关键词: Clinical significance 、 Biomarker (medicine) 、 Pyruvate kinase 、 Adenocarcinoma 、 Medicine 、 Oncology 、 Lung cancer 、 Stage (cooking) 、 Internal medicine 、 PKM2 、 Cancer 、 Pathology
摘要: Metabolism of tumor tissue differs from the normal one by intensity protein synthesis and glycolysis. The dimeric pyruvate kinase (PKM2) is a specific enzyme for aim this study was to determine relationship between activity PKM2 type stage non-small cell lung cancer (NSCLC). A second objective compare expression with disease progression prognosis. We studied 65 patients divided into two groups: 45 20 non-cancer healthy subjects taken as control. serum assessed spectrophotometrically. found that greater, on average, 136 % adenocarcinoma 126 squamous carcinoma compared present in control subjects. higher associated only Stage III (p < 0.001). Sensitivity marker 79 81 specificity 50 both types. conclude NSCLC than level advanced cancer. Nonetheless, low assessment makes it limited utility diagnosis or evaluation progression.
springer.com
sci-hub.se 参考文章(25)
Marcellus Simadibrata, Murdani Abdullah, Ari Fahrial Syam, Achmad Fauzi, Abdul Aziz Rani, The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening. Acta medica Indonesiana. ,vol. 44, pp. 94- 99 ,(2012)
Toepler M, Ngoumou B, Hardt Pd, Rupp J, Kloer Hu, Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Research. ,vol. 23, pp. 851- 853 ,(2003)
Joachim Schneider, Guntram Schulze, Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Research. ,vol. 23, pp. 5089- 5093 ,(2003)
Bo Zhang, Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls World Journal of Gastroenterology. ,vol. 10, pp. 1643- 1646 ,(2004) , 10.3748/WJG.V10.I11.1643
Beata Muszczynska-Bernhard, Christopher Kobierzycki, Bartosz Pula, Aleksandra Piotrowska, Bozena Werynska, Piotr Dziegiel, Dariusz Rakus, The Lack of Evidence for Correlation of Pyruvate Kinase M2 Expression with Tumor Grade in Non-small Cell Lung Cancer Anticancer Research. ,vol. 34, pp. 3811- 3817 ,(2014)
Yogesh Kumar, Inigo R Pinedo, Niteen Tapuria, Abigail Zabron, Brian R Davidson, None, A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases. European Journal of Gastroenterology & Hepatology. ,vol. 20, pp. 1006- 1011 ,(2008) , 10.1097/MEG.0B013E3282F857A7
N. Voorzanger-Rousselot, P. Garnero, Biochemical markers in oncology. Part I: Molecular basis. Part II: Clinical uses Cancer Treatment Reviews. ,vol. 33, pp. 230- 283 ,(2007) , 10.1016/J.CTRV.2007.01.008
Edward B. Garon, Heather R. Christofk, Wylie Hosmer, Carolyn D. Britten, Agnes Bahng, Matthew J. Crabtree, Candice Sun Hong, Naeimeh Kamranpour, Sharon Pitts, Fairooz Kabbinavar, Cecil Patel, Erika von Euw, Alexander Black, Evangelos D. Michelakis, Steven M. Dubinett, Dennis J. Slamon, Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. ,vol. 140, pp. 443- 452 ,(2014) , 10.1007/S00432-014-1583-9
Clifton F. Mountain, Revisions in the International System for Staging Lung Cancer Chest. ,vol. 111, pp. 1710- 1717 ,(1997) , 10.1378/CHEST.111.6.1710
Rui Li, Jianjun Liu, Huiping Xue, Gang Huang, Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: a systematic review and meta-analysis. International Journal of Cancer. ,vol. 131, pp. 1837- 1845 ,(2012) , 10.1002/IJC.27442